Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Blonde

Showing results (71-80 of 144) with videos related to

Pageof 15
Sort By:
Current Medical Research and Opinion|April 20, 2018
The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US populationLawrence Blonde, Chakkarin Burudpakdee, Victoria Divino, et al.
The Journal of Clinical Endocrinology and Metabolism|August 2, 2012
Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trialMarcia A Testa, Jasvinder Gill, Max Su, et al.
Journal of Clinical & Translational Endocrinology|October 26, 2017
The interdisciplinary team in type 2 diabetes management: Challenges and best practice solutions from real-world scenariosMargaret McGill, Lawrence Blonde, Juliana C N Chan, et al.
Lancet (London, England)|May 27, 2015
Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority studyLawrence Blonde, Johan Jendle, Jorge Gross, et al.
Endocrinology, Diabetes & Metabolism|July 12, 2019
Clinical implications of prolonged hyperglycaemia before basal insulin initiation in type 2 diabetes patients: An electronic medical record database analysisDenis Raccah, Bruno Guerci, Mayank Ajmera, et al.
Cardiovascular Diabetology|January 15, 2017
Differential effects of glucagon-like peptide-1 receptor agonists on heart rateMartin Lorenz, Francesca Lawson, David Owens, et al.
Pharmacoeconomics|August 16, 2005
Real-world trials to answer real-world questionsNick Freemantle, Lawrence Blonde, Bjorn Bolinder, et al.
Diabetes Research and Clinical Practice|September 23, 2017
Insulin regimens and glycemic control in different parts of Europe over 4years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional studyLawrence Blonde, Michel Marre, Maya Vincent, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 29, 2012
Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%Allen B King, Eduard Montanya, Richard E Pratley, et al.
Journal of Diabetes and Its Complications|February 10, 2015
Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitusJohn P H Wilding, Lawrence Blonde, Lawrence A Leiter, et al.
Pageof 15

Showing results (71-80 of 144) with videos related to

Sort By:
Pageof 15
Current Medical Research and Opinion|April 20, 2018
The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US populationLawrence Blonde, Chakkarin Burudpakdee, Victoria Divino, et al.
The Journal of Clinical Endocrinology and Metabolism|August 2, 2012
Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trialMarcia A Testa, Jasvinder Gill, Max Su, et al.
Journal of Clinical & Translational Endocrinology|October 26, 2017
The interdisciplinary team in type 2 diabetes management: Challenges and best practice solutions from real-world scenariosMargaret McGill, Lawrence Blonde, Juliana C N Chan, et al.
Lancet (London, England)|May 27, 2015
Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority studyLawrence Blonde, Johan Jendle, Jorge Gross, et al.
Endocrinology, Diabetes & Metabolism|July 12, 2019
Clinical implications of prolonged hyperglycaemia before basal insulin initiation in type 2 diabetes patients: An electronic medical record database analysisDenis Raccah, Bruno Guerci, Mayank Ajmera, et al.
Cardiovascular Diabetology|January 15, 2017
Differential effects of glucagon-like peptide-1 receptor agonists on heart rateMartin Lorenz, Francesca Lawson, David Owens, et al.
Pharmacoeconomics|August 16, 2005
Real-world trials to answer real-world questionsNick Freemantle, Lawrence Blonde, Bjorn Bolinder, et al.
Diabetes Research and Clinical Practice|September 23, 2017
Insulin regimens and glycemic control in different parts of Europe over 4years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional studyLawrence Blonde, Michel Marre, Maya Vincent, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 29, 2012
Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%Allen B King, Eduard Montanya, Richard E Pratley, et al.
Journal of Diabetes and Its Complications|February 10, 2015
Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitusJohn P H Wilding, Lawrence Blonde, Lawrence A Leiter, et al.
Pageof 15